Randomized trial of standard therapy with or without poly I:C in patients with superficial bladder cancer

Abstract
Thirty‐two patients with superficial urinary bladder tumors were stratified for four variables and randomized after complete transurethral resection and/or fulguration of tumor to receive standard therapy with or without intravenous Poly I:C. Cystoscopies were performed at three‐ to four‐month intervals for up to 48 months. While there was no statistically significant difference in the tumor recurrence rates in the two groups during the first year, a significant increase (P = 0.003) in survival at four years was observed between the Poly I:C group and the control group. The difficulties in evaluating the efficacy of anti‐neoplastic agents in the treatment of superficial bladder tumors are discussed.